Prognostic index for adult patients with acute myeloid leukemia in first relapse

Journal of Clinical Oncology

Volumn 23, Issue 9, 2005, Pages 1969-1978

  Breems, Dimitri A ^a   Van Putten, Wim L J ^a   Huijgens, Peter C ^a   Ossenkoppele, Gert J ^a   Verhoef, Gregor E G ^a   Verdonck, Leo F ^a   Vellenga, Edo ^a   De Greef, Georgine E ^a   Jacky, Emanuel ^a   Van der Lelie, Johannes ^a   Boogaerts, Marc A ^a   Löwenberg, Bob ^a  

^a SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE; BUSULFAN; CD33 ANTIBODY; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; MOLGRASTIM; MONOCLONAL ANTIBODY; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATIENT DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SCORING SYSTEM; ACUTE DISEASE; CLINICAL TRIAL; GENETICS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYELOID LEUKEMIA; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; SALVAGE THERAPY; SURVIVAL;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 20244361887     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.027     Document Type: Article

References (24)

1. Löwenberg B, Downing JR, Burnett A: Acute myeloid leukemia. N Engl J Med 341: 1051-1062, 1999
2. Burnett AK: Acute myeloid leukemia: Treatment of adults under 60 years. Rev Clin Exp Hematol 6:26-45, 2002
3. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
4. Wheatley K, Burnett AK, Goldstone AH, et al: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived form the MRC AML 10 trial. Br J Haematol 107:69-79, 1999
5. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96:4075-4083, 2000
6. Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia group B (CALBG 8461). Blood 100:4325-4336, 2002
7. Leopold LH, Willemze R: The treatment of acute myeloid leukemia in first relapse: A comprehensive review of the literature. Leuk Lymphoma 43:1715-1727, 2002
8. Lee S, Tallman MS, Oken MM, et al: Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Leukemia 14: 1345-1348, 2000
9. Kantarjian HM, Keating MJ, Walters RS, et al: The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 6:232-238, 1988
10. Mortimer J, Blinder MA, Schulman S, et al: Relapse of acute leukemia after marrow transplantation: Natural history and results of subsequent therapy. J Clin Oncol 7:50-57, 1989
11. Keating MJ, Kantarjian H, Smith TL, et al: Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7:1071-1080, 1989
12. Uhlman DL, Bloomfield CD, Hurd DD, et al: Prognostic factors at relapse for adults with acute myeloid leukemia. Am J Hematol 33:110-116, 1990
13. Angelov L, Brandwein JM, Baker MA, et al: Results of therapy for acute myeloid leukemia in first relapse. Leuk Lymphoma 6:15-24, 1991
14. Thalhammer F, Geissler K, Jager U, et al: Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: A retrospective single-center study. Ann Hematol 72:216-222, 1996
15. Kern W, Schoch C, Haferlach T, et al: Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance of cytogenetic abnormalities. Leukemia 14:226-231, 2000
16. Hiddemann W, Martin WR, Sauerland CM, et al: Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD9) in 150 patients with relapse after standardized first line therapy. Leukemia 4:184-188, 1990
17. Estey E, Kornblau S, Pierce S, et al: A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 88:756, 1996
18. Löwenberg B, Boogaerts MA, Daenen SMGJ, et al: Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 15:3496-3506, 1997
19. Löwenberg B, Van Putten W, Theobald M, et al: Effect of priming with granulocyte-colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 349:743-752, 2003
20. Mitelman F ICSN 1995: An international system for human cytogenetic nomenclature. Basel, Switzerland, Karger, 1995
21. Barlow RE, Bartholomew DJ, Bremner JM, et al: Statistical Inference Under Restrictions. New York, NY, Wiley, 1972
22. Efron B, Tibshirani R: An Introduction to the Bootstrap. New York, NY, Chapman and Hall, 1993
23. Harrell FE: Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression and Survival Analysis. New York, NY, Springer, 2001
24. Kern W, Haferlach T, Schnittger S, et al: Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: Implications for resistance against therapy. Leukemia 16:2084-2091, 2002